Skip to main content

Table 2 Comparison of ischemic risk prevention and bleeding with clopidogrel plus aspirin (clop + ASA) versus aspirin plus placebo (ASA + placebo).

From: Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy

  Ischemic Events Bleeding Events
Trial
(observation period)
clop + ASA (%) ASA + placebo (%) p NNT clop + ASA
(%)
ASA + placebo
(%)
p NNH
Cure [36]
(1 year)
9.3 11.4 <0.001 47.6 major 3.7
minor 5.1
total 8.5
major 2.7
minor 2.4
total 5.0
<0.001
<0.001
<0.001
100
37
28.6
Credo [38]
(1 years)
8.5 11.2 0.02 37.0 severe 8.8
minor 5.3
severe 6.7
minor 5.6
0.07
0.92
250
Charisma [3]
(2.5 years)
6.8 7.3 0.22 200 severe 1.7
moderate 2.1
moderate + severe 3.8
severe1.3
moderate 1.3
moderate + severe 2.6
0.09
<0.001
<0.001
250
125
83.3
  1. Comparison of ischemic risk prevention and bleeding with clopidogrel plus aspirin (clop + ASA) versus aspirin plus placebo (ASA + placebo). Aspirin plus clopidogrel increased the incidence of bleeding events compared with aspirin plus placebo. Comparing the primary endpoint reduction with the two treatments, it appears that increased frequency of bleeding can limit the benefits of combined therapy.
  2. NNT: Number Needed to Treat
  3. NNH: Number Needed to Harm